TLR-9 and OX40 strategy | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1518 of 1524  at  9/4/2019 2:03:57 PM  by

clsm

The following message was updated on 9/4/2019 2:04:17 PM.

 In response to msg 1516 by  raferjack
view thread

Re: TLR-9 and OX40 strategy

Dr. Levy in running two trials and testing DVAX's SD-101 and BMY's BMS-986178.
 
In patients with low-grade B-cell non-hodgkin lymphomas (NCT03410901) they receive radiation therapy on days 1-2, TLR9 agonist SD-101 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 intravenously (IV) on days 3, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable.
 
For patients with with advanced or metastatic solid tumours (NCT03831295) they eceive TLR9 agonist SD-101 intratumorally (IT) on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and intravenously (IV) over 30 minutes on days 8, 29 and 58.

There is an expansion cohort: TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 86
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...